FORTRESS BIOTECH, INC. (NASDAQ:FBIO) Files An 8-K Results of Operations and Financial Condition
Item 2.02.
|
Results of Operations and Financial Condition. |
On March 16, 2017, Fortress Biotech, Inc. issued a press release
announcing its financial results for the year ended December 31,
2016. A copy of the press release is attached hereto as
Exhibit99.1 and is incorporated herein in its entirety by
reference.
The information in this Item2.02 (including Exhibit 99.1) shall
not be deemed filed for purposes of Section18 of the Securities
Exchange Act of 1934 (the Exchange Act) or otherwise subject to
the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933 or the Exchange Act, except as expressly set forth by
specific reference in such a filing.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits |
| Exhibit No. | Description |
| 99.1 | Press release dated March 16, 2017. |
About FORTRESS BIOTECH, INC. (NASDAQ:FBIO)
Fortress Biotech, Inc., formerly Coronado Biosciences, Inc., is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products. The Company’s product, CNDO-109, is a lysate (disrupted Closteroviridae (CTV)-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor Natural Killer (NK) cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia (ALL). The Company holds the license to develop and commercialize CNDO-109 to activate NK cells for the treatment of cancer-related and other conditions, and a non-exclusive license to certain clinical data solely for use in the Investigational new drug (IND) for CNDO-109. The Company is conducting the Phase I clinical studies of CNDO-109. FORTRESS BIOTECH, INC. (NASDAQ:FBIO) Recent Trading Information
FORTRESS BIOTECH, INC. (NASDAQ:FBIO) closed its last trading session down -0.04 at 3.61 with 278,037 shares trading hands.
